Related Experiment Videos
Suspected carbamazepine-induced hepatotoxicity
M Morales-Diaz1, E Pinilla-Roa, I Ruiz
1Infectious Disease Service, Hospital Luis Calvo Mackenna, Santiago, Chile.
Insights
Carbamazepine, an anticonvulsant, can cause severe liver injury in children. Prompt drug withdrawal and corticosteroid treatment led to recovery, highlighting the need for pediatric-specific adverse event assessments.
Area of Science:
- Pediatric Hepatology
- Clinical Pharmacology
- Adverse Drug Event Analysis
Background:
- Carbamazepine is a widely used anticonvulsant for epilepsy.
- Hepatotoxicity is a known, albeit rare, adverse effect of carbamazepine.
- Assessing causality of adverse drug events is crucial for patient safety.
Observation:
- A pediatric patient on therapeutic carbamazepine doses developed severe hepatitis and hepatic insufficiency.
- The patient's liver function improved significantly after discontinuing carbamazepine and initiating corticosteroid therapy.
Findings:
- The Roussel UCLAF causality assessment method was applied, yielding a score of 8 for this acute hepatocellular event.
- This score indicates a probable causal link between carbamazepine and the observed liver injury.
- The case highlights the potential for severe hepatic adverse events in children treated with carbamazepine.
Implications:
- The Roussel UCLAF method offers a comprehensive approach to causality assessment in drug-induced liver injury.
- Adaptation of causality assessment tools is necessary for accurate evaluation of adverse events in the pediatric population.
- This case underscores the importance of vigilant monitoring for hepatotoxicity in children receiving carbamazepine.
Abstract:
Carbamazepine is a potent anticonvulsant agent with proven efficacy in the treatment of partial and tonic-clonic seizures. An epileptic child treated with therapeutic dosages of carbamazepine developed severe hepatitis and hepatic insufficiency. She had a positive response to withdrawal of the drug and administration of corticosteroids. The Roussel UCLAF method for estimating causality of the adverse event was applied for an acute hepatocellular problem, with a final score of 8. This method has advantages over other tools because it involves many clinical factors that give additional guides to clinicians in patients with liver injury, but it must be adapted for adverse events in the pediatric population.